

# **CCSG Electronic Data Guide (eData 1.0)**

National Institutes of Health/ DHHS  
National Cancer Institute  
Office of Cancer Centers

**6116 Executive Blvd.  
Bethesda, MD 20892-8345  
<http://cancercenters.cancer.gov/>**

**February 5, 2013**

**CONTENTS**

**INTRODUCTION ..... 1**

    BACKGROUND.....1

    PURPOSE .....2

    OCC DATABASE .....3

    REFERENCES .....5

**SECTION 1. DATA TABLES 1A, 1B, 1C, AND 1D ..... 6**

    1.1 DATA TABLE 1A - SENIOR LEADERSHIP.....6

    1.2 DATA TABLE 1B - PROGRAMS, LEADERS, AND PROGRAM CODES .....7

    1.3 DATA TABLE 1C - CANCER CENTER MEMBERSHIP .....9

**SECTION 2. DATA TABLES 2A AND 2B - ACTIVE FUNDED PROJECTS..... 12**

    2.1 DATA TABLE 2A - ACTIVE FUNDED PROJECTS .....12

    2.2 DATA TABLE 2B- ACTIVE FUNDED PROJECTS .....14

**SECTION 3.....DATA TABLE 3 - NEWLY REGISTERED PATIENTS/PARTICIPATION OF PATIENTS IN INTERVENTIONAL TREATMENT TRIALS BY ANATOMIC CANCER SITE ..... 15**

**SECTION 4. DATA TABLE 4 - INFORMATION ON CLINICAL RESEARCH STUDIES .... 19**

**APPENDIX A. DATA TABLE EXAMPLE FORMAT ..... 22**

    DATA TABLE 1A EXAMPLE FORMAT ..... 1

    DATA TABLE 1B EXAMPLE FORMAT ..... 2

    DATA TABLE 1C EXAMPLE FORMAT ..... 3

    DATA TABLE 1D EXAMPLE FORMAT ..... 4

    DATA TABLE 2A - EXAMPLE FORMAT ..... 5

    DATA TABLE 2B EXAMPLE FORMAT ..... 10

    DATA TABLE 3 - EXAMPLE FORMAT ..... 17

    DATA TABLE 4 - EXAMPLE FORMAT ..... 11

**FIGURES**

    FIGURE 1: THE DATA TABLE I/O OVERVIEW .....2

**TABLES**

    FIGURE 1: THE DATA TABLE I/O OVERVIEW .....2

    TABLE 1: OVERVIEW OF DATA TYPES.....4

    TABLE 1-1: DATA TABLE 1A COLUMN DEFINITIONS .....6

    TABLE 1-2: DATA TABLE 1B COLUMN DEFINITIONS .....7

    TABLE 1-3: DATA TABLE 1C COLUMN DEFINITIONS .....9

    TABLE 1-4: DATA TABLE 1D COLUMN DEFINITIONS .....10

    TABLE 2-1: DATA TABLE 2A COLUMN DEFINITIONS .....12

    TABLE 2-2: DATA TABLE 2B COLUMN DEFINITIONS .....14

    TABLE 3-1: DATA TABLE 3 COLUMN DEFINITIONS .....15

    TABLE 4-1: DATA TABLE 4 COLUMN DEFINITIONS .....19


## INTRODUCTION

### Background

The Office of Cancer Centers (OCC) at the National Cancer Institute (NCI) is responsible for overseeing a portfolio of grants that support cancer research for NCI-designated Cancer Centers across the U.S. The OCC program was established by the 1971 National Cancer Act and serves as a major platform for advancing NCI initiatives.

The CCSG Electronic Data Guide itemize the Center's formal Research Programs, Shared Resources, base of funded research projects, patient information, clinical research protocols, and a comparison of current and requested budgets. The primary reason for standard Data Table is to ensure consistency and thoroughness during the peer review of competing applications. Each year the Centers are required to send an electronic copy of the Data Table (1-4) information in Excel (.xls or .xlsx) or MS-ACCESS (accdb) format directly to the OCC at [ccsgdata@mail.nih.gov](mailto:ccsgdata@mail.nih.gov).

The synthesized data from all of the cancer centers are further verified for consistency and imported into the OCC SQL-Server database. In addition, the aggregate Data Tables are presented on the OCC website, <http://cancercenters.cancer.gov>. The figure 1-1 shows the overview of the input and output (I/O) of the Data table:



**Figure 1: The Data Table I/O Overview**

## **Purpose**

The purpose of the CCSG Electronic Data Guide, herein referred to as eData, document is to present a description and standard format of the electronic data table submission. This format will allow Centers' information to be processed and shared in a uniform and consistent matter. The eData seeks to accomplish the following:

- facilitate data standardization;
- streamline the data importing process;
- improve data quality and analysis; and
- simplify data management and reporting.

The distinction between the eData and the CCSG Data Guide is subtle but important. This document describes each of the data table's field columns at a granular level with significant technical detail. It identifies each data column, definition, type and its usage; it also includes example(s) for each of the data tables.

Please refer to CCSG Data Guide for detailed information including definitions and examples. Note that Data Table 5 is not required to be submitted electronically; therefore, it is excluded from this document.

## OCC Database

As a step toward improving web interactivity, the current OCC website will be redesigned to a more dynamic or database-driven website. The centralized database that supports this enhanced website application is called the OCCdb. The OCCdb is where all the tables, views, stored procedures, and triggers are created.

Tables are commonly referred to as entities in the database. Data columns (fields) are commonly referred to as attributes for a particular table. In OCCdb the underscore character will not be used in a table name or column name. Furthermore, all tables in the OCC databases will begin with an uppercase letter followed by a series of upper and lowercase letters. Meaningful table names have been chosen to identify the overall purpose of the database tables (*e.g.*, CenterDetail).

Each data column in the table has a data type, which defines what kind of data can be stored in a column.

**Note** the distinction between a blank space and a NULL value. A blank space is a character string while a NULL is an unknown value. If the data is not available or applicable, use NULL by leaving the column empty.

Table 1-1 provides an overview of data types that are used in the OCCdb.

**Table 1: Overview of Data Types**

Data Type	Abbr	Syntax	Valid Entry	Description
Character	CHAR	CHAR( <i>n</i> )	A character or NULL value	Fixed-length, non-Unicode string data. <i>n</i> defines the string length and must be a value from 1 through 8,000. It is used for data that are a mixture of numbers and letters (alphanumeric data).
Datetime	-	DATETIME	Date/time or NULL value	Stores exact date/time values
Varchar [ ( <i>n</i>   max ) ]	-	VARCHAR( <i>n</i> ), or VARCHAR(max)		Variable-length, standard character string data. <i>n</i> defines the string length and can be a value from 1 through 8,000.
Float	-	FLOAT	Numeric , zero, or NULL value	Uses the floating-point numbers with 16 or fewer significant digits
Integer	INT	INT	Numeric, zero, or NULL value	Stores whole numbers (no decimal point)
Nvarchar [ ( <i>n</i>   max ) ]	-	NVARCHAR( <i>n</i> ) or NVARCHAR(max)	A character string, blank space (s) or NULL value	Variable-length Unicode character data. <i>N</i> can be a value from 1 through 4,000.

## References

The primary references related to this document are located on the following website:  
[http://cancercenters.cancer.gov/grants\\_funding/index.html](http://cancercenters.cancer.gov/grants_funding/index.html) site references:

- 2013 CCSG Guidelines and CCSG Data Guide
- 2103 CCSG Electronic Data Guide (eData)
- FAQs

## SECTION 1. DATA TABLES 1A, 1B, 1C, AND 1D

### 1.1 Data Table 1A - Senior Leadership

Create one record for each individual senior leader and use the following column name and definitions for clarity and uniformity:

**Table 1-1: Data Table 1A Column Definitions**

Column Name	SQL-Server Data Type	Definition
Grant Number	int	The unique identification number for the P30 grant ( <i>e.g.</i> , 6929, 103693)
ReportingDate	DateTime MM/DD/YYYY	Center-defined reporting date
LastName	varchar(25)	The last name of the senior leader
FirstName	varchar(25)	The first name of the senior leader
MiddleName	varchar(25)	The middle name or initial of the senior leader
IsNew	char(1)	Indicate whether this is a new leader; use “Y” for yes and “N” for no.
Title	varchar(100)	The title of the senior leader
Degree1	varchar(15)	First academic degree acronym or abbreviation of the senior leader ( <i>e.g.</i> , PhD)
Degree2	varchar(15)	Second academic degree acronym or abbreviation of the senior leader ( <i>e.g.</i> , MD)
Degree3	varchar(15)	Third academic degree acronym or abbreviation of the senior leader ( <i>e.g.</i> , MS)

Ctrl-Click on the following link for the [Data Table 1A Example Format](#)

## 1.2 Data Table 1B - Programs, Leaders, and Program Codes

Create one record for each program; use the following column names and definitions for clarity and uniformity. For any program with multiple leaders, please create an individual record for each leader.

**Table 1-2: Data Table 1B Column Definitions**

Column Name	Data Type	Definition
GrantNumber	Int	The unique identification number for the P30 grant ( <i>e.g.</i> , 6929, 103693)
ReportingDate	DateTime MM/DD/YYYY	Center-defined reporting date
ProgCode	Varchar(5)	The alphanumeric code that identifies the clinical research program. This code is also defined in Data Tables 2 and 4 ( <i>e.g.</i> , 01, 02, XT, or BC)
ProgName	Varchar(255)	The name of the research program
IsNewProg	Char(1)	Indicate whether this is a new research program; use 'Y' for yes and 'N' for no.  <i>Note</i> that Research Programs are peer-reviewed components of the CCSG. Therefore, they cannot be added or deleted during a non-competing (Type 5) year without prior approval from the NCI's Office of Cancer Centers (OCC). If your Center is considering a change in Programs during a non-competing year, please contact your Program Officer.
IsDevProg	Char(1)	Indicate whether if the research program listed is supported by developmental funds; use 'Y' for yes and 'N' for no
IsMultiLeader	Char(1)	Indicate whether if this is a multiple leader program; use 'Y' for yes and 'N' for no
LastName	Varchar(25)	The last name of the research program leader
FirstName	Varchar(25)	The first name of the research program leader
MiddleName	Varchar(25)	The middle name or initial of the research program leader
Degree1	Varchar(15)	First academic degree acronym or abbreviation of the director ( <i>e.g.</i> , PhD)
Degree2	Varchar(15)	Second academic degree acronym or abbreviation of the director ( <i>e.g.</i> , MD)
Degree3	Varchar(15)	Third academic degree acronym or abbreviation of the director ( <i>e.g.</i> , MS)
IsNew	Char(1)	Indicate whether this is a new leader; use 'Y' for yes and 'N' for no

## CCSG Electronic Data Table Guide (eData)

---

<b>Column Name</b>	<b>Data Type</b>	<b>Definition</b>
NoOfMember	Int	The number of members assigned to the research program

Ctrl-Click on the following link for the [Data Table 1B Example Format](#)

### 1.3 Data Table 1C - Cancer Center Membership

Create one record for each total number and use the following column names and definitions for clarity and uniformity:

**Table 1-3: Data Table 1C Column Definitions**

Column Name	Data Type	Definition
GrantNumber	Int	The unique identification number for the P30 grant ( <i>e.g.</i> , 6929, 103693)
ReportingDate	DateTime MM/DD/YYYY	Center-defined reporting date
AlignedNumber	Int	The number of the programmatically aligned members (Individuals)
NonAlignedNumber	Int	The number of non-programmatically aligned members (Individuals)
GrandTotal	Int	The total number of Cancer Center Members (Individuals)

Ctrl-Click on the following link for the [Data Table 1C Example Format](#)

Data Table 1D - Shared Resources

Create one record for each shared resource and use the following column names and definitions for clarity and uniformity. *For a share resource with multiple directors, please create an individual record for each director.*

**Table 1-4: Data Table 1D Column Definitions**

Column Name	Data Type	Definition
GrantNumber	Int	The unique identification number for the P30 grant ( <i>e.g.</i> , 6929, 103693)
ReportingDate	DateTime MM/DD/YYYY	Center-defined reporting date
SRName	Varchar(255)	The name of the shared resource.
SRSSubCat1	Float	A 3-digit codes to indicate the shared resource subcategory ( <i>e.g.</i> , 1.37)
SRSSubCat2	Float	A 3-digit codes to indicate the shared resource subcategory ( <i>e.g.</i> , 2.10)
SRSSubCat3	Float	A 3-digit codes to indicate the shared resource subcategory ( <i>e.g.</i> , 7.04)
IsNew	Char(1)	Indicate whether this is a new leader; use 'Y' for yes and 'N' for no
IsNewSR	Char(1)	Indicate whether this is a new Shared Resource; use 'Y' for yes, and 'N' for no.  <i>Note that Shared Resources are peer-reviewed components of the CCSG. Therefore, they cannot be added or deleted during a non-competing (Type 5) year without prior approval from the NCI's Office of Cancer Centers (OCC). If your Center is considering a change in Shared Resources during a non-competing year, please contact your Program Officer.</i>
IsDevSR	Char(1)	Indicate whether if the shared resource listed is supported by developmental funds; use 'Y' for yes and 'N' for no
IsMultiDirector	Char(1)	Indicate whether this shared resource is managed by multiple directors. Use 'Y' for yes and 'N' for no
LastName	Varchar(25)	The last name of the shared resource leader
FirstName	Varchar(25)	The first name of the shared resource leader
MiddleName	Varchar(25)	The middle name or initial of the shared resource leader
Degree1	Varchar(15)	First academic degree acronym or abbreviation of the director ( <i>e.g.</i> , PhD)
Degree2	Varchar(15)	Second academic degree acronym or abbreviation of the director ( <i>e.g.</i> , MD)

## CCSG Electronic Data Table Guide (eData)

---

<b>Column Name</b>	<b>Data Type</b>	<b>Definition</b>
Degree3	Varchar(15)	Third academic degree acronym or abbreviation of the director ( <i>e.g.</i> , MS)

Ctrl-Click on the following link for the [Data Table 1D Example Format](#)

## SECTION 2. DATA TABLES 2A AND 2B - ACTIVE FUNDED PROJECTS

### 2.1 Data Table 2A - Active Funded Projects

For a center-defined 12-month reporting period, create one record for each funded project and use the following column names and definitions. *For each project with multiple PIs or leaders, please create an individual record for each PI or leader.*

**Table 2-1: Data Table 2A Column Definitions**

Column Name	Data Type/Format	Definition
GrantNumber	Int	The unique identification number for the P30 grant ( <i>e.g.</i> , 6929, 12185)
ReportingDate	DateTime MM/DD/YYYY	Center-defined reporting date
LastName	Varchar(25)	The last name of the PI from your Center who is responsible for this project
FirstName	Varchar(25)	The first name or initial of the PI from your Center who is responsible for this project
MiddleName	Varchar(25)	The middle name or initial of the PI from your Center who is responsible for this project
IsMultiPI	Char(1)	Indicate whether it is a multiple PI project; use “Y” for yes and “N” for no.
IsPeerRev	Char(1)	Indicate whether the Projects that are awarded by NCI, NIH, or NCI-approved peer-review organizations; use “Y” for yes and “N” for no.
IsSubContract	Char(1)	Indicate whether the project is a subcontract; use “Y” for yes and “N” for no <i>Please note that # is used in the CCSG Data Guide</i>
FundingSource	Varchar(25)	The specific name of the financial sponsor for the project ( <i>e.g.</i> , NCI, ACS)
ProjNo	Varchar(100)	Commonly referred to as the application number or grant number. This unique identification number for the grant is composed of the type code, activity code, Institute code, serial number, support year, and/or suffix code ( <i>e.g.</i> , 1R01CA059736-01)
ProjStartDate	DateTime MM/DD/YYYY	Official date a grant award begins; same as the first day of the first budget period ( <i>e.g.</i> , 6/1/2010)
ProjEndDate	Date/Time	Official date a grant award ends; same as the last day of the final

CCSG Electronic Data Table Guide (eData)

Column Name	Data Type/Format	Definition
	MM/DD/YYYY	budget period. (e.g., 5/30/2015)
ProjTitle	Varchar(8000)	The official title of the research project being carried out at your institution (e.g., Regulation of mitochondrial inheritance in yeast)
AnnualProjDirectCost	Int	Annual Costs that can be identified specifically with a particular sponsored project, other institutional activity, or that can be directly assigned to such activities relatively easily with a high degree of accuracy (e.g., 1560000) <i>Do not include a comma (,) or a dollar sign (\$) in the figure.</i>
AnnualProjTotCost	Int	The total allowable annual costs (both direct costs and facilities and administrative costs) incurred by the grantee to carry out a grant-supported project or activity (e.g., 1560000) <i>Do not include a comma (,) or a dollar sign (\$) in the figure.</i>
ProgCode	Varchar(15)	An alphanumeric code that identifies Research Program affiliated with the clinical research study as defined by the Center in Data Table 1B (e.g., 42, XY) Identify all training grants, including the F, K and T series NIH grants, with the program code "T".
ProgPercent	Int	The proportion of research attributable to the identified Research Program (e.g., 20, 100). <i>Do not include the percent sign (%) in the figure.</i>
AnnualProgDirectCost	Int	Annual Direct Costs that support research carried out in the Center's Research Programs (e.g., 1560000) <i>Do not include a comma (,) or a dollar sign (\$) in the figure.</i>
AnnualProgTotCost	Int	Annual Total Costs that support research carried out in the Center's Research Programs (e.g., 1560000) <i>Do not include a comma (,) or a dollar sign (\$) in the figure.</i>

Ctrl-Click on the following link for the [Data Table 2A Example Format](#).

## 2.2 Data Table 2B- Active Funded Projects

List the total number of projects and the sum of direct and total costs for each major funding agency category as follows: NCI, other NIH, other Peer and Non Peer-Reviewed (Industry-sponsored and Other). Provide subtotals and a grand total where indicated.

**Table 2-2: Data Table 2B Column Definitions**

Column Name	SQL-Server Data Type	Definition
GrantNumber	Int	The unique identification number for the P30 grant ( <i>e.g.</i> , 6929, 103693)
ReportingDate	DateTime MM/DD/YYYY	Center-defined reporting date
NCITotalNo	Int	The total number of NCI projects
NCIDirectCost	Int	The direct cost amount of the NCI projects
NCITotalCost	Int	The total cost amount of the NCI projects
OthNIHTotalNo	Int	The total number of NIH projects
OthNIHDirectCost	Int	The direct cost amount of the NIH projects
OthNIHTotalCost	Int	The total cost amount of the NIH projects
OthPeerTotalNo	Int	Total number of the other peer-reviewed projects
OthPeerDirectCost	Int	The direct cost amount of the other peer-reviewed projects
OthPeerTotalCost	Int	The total cost amount of the other peer-reviewed projects
IndustryNonPeerTotalNo	Int	The total number of Industry non peer-reviewed projects
IndustryNonPeerDirectCost	Int	The direct cost amount of the industry non peer-reviewed projects
IndustryNonPeerTotalCost	Int	The total cost amount of the industry non peer-reviewed projects
OthNonPeerTotalNo	Int	The total number of the other non-peer-reviewed projects
OthNonPeerDirectCost	Int	The direct cost amount of the other non-peer-reviewed projects
OthNonPeerTotalCost	Int	The total cost amount of the other non-peer-reviewed projects

Ctrl-Click on the following link for the [Data 2B - Format Sample](#).

### SECTION 3. DATA TABLE 3 - NEWLY REGISTERED PATIENTS/PARTICIPATION OF PATIENTS IN INTERVENTIONAL TREATMENT TRIALS BY ANATOMIC CANCER SITE

For the 12-month period as defined by the Cancer Center, create one record for reportable cancers and use the following column names and definitions for clarity and uniformity.

**Note to Consortium Cancer Centers and Cancer Centers with affiliated institutions:** Submit separate Data Table 3 tables for each consortium partner and/or affiliated institution (*e.g.*, pediatric hospital) that is a formal component of the Cancer Center but maintains a separate cancer registry. Do not include loosely affiliated community partners.

**Table 3-1: Data Table 3 Column Definitions**

Column Name	SQL-Server Data Type	Definition
GrantNumber	Int	The unique identification number for the P30 grant ( <i>e.g.</i> , 6929, 103693)
ReportingStartDate	DateTime MM/DD/YYYY	The date on which the center-defined 12-month reporting period started
ReportingEndDate	DateTime MM/DD/YYYY	The date on which the center-defined 12-month reporting period ended
ReportingSource	Varchar(255)	Name of Reporting Source. For consortium centers or those with affiliated institutions, indicate the specific name of the reporting institution.
PrimarySite	Varchar(255)	Reportable Cancers. Malignancies with an International Classification of Diseases for Oncology (ICD) behavior code of 2 or 3 should be reported, in accordance with the established requirements of registry standard setting organizations. Please refer to the ICD Codes on the OCC website: <a href="http://cancercenters.cancer.gov/grants_funding/index.html">http://cancercenters.cancer.gov/grants_funding/index.html</a> .
RegisteredPatient	Int	Newly registered patients are those patients seen face-to-face and recorded in the Cancer Center’s Cancer Registry for the first time for that diagnosis during the reporting period. They include inpatients and outpatients who: 1) are newly diagnosed and/or receiving first course of treatment at the Cancer Center, <i>i.e.</i> , equivalent to American College of Surgeons (ACoS) – defined analytic case codes 00 – 22.

CCSG Electronic Data Guide (eData)

Column Name	SQL-Server Data Type	Definition
		<p><a href="http://www.facs.org/cancer/coc/fords/FORDS_for_2011_01012011.pdf">http://www.facs.org/cancer/coc/fords/FORDS_for_2011_01012011.pdf</a> pages 91 and 92), or 2)] have recurrent or persistent disease and are referred to the Cancer Center for evaluation and treatment, <i>i.e.</i>, equivalent to ACoS-defined non-analytic code 32.</p>
EnrolledPatient	Int	<p>Total patients newly enrolled in interventional treatment trials                      Interventional treatment trials are protocols designed to evaluate one or more interventions (<i>e.g.</i>, drugs, radiation, surgery, biological agents, devices, behaviors, etc) for treating a disease, syndrome, or condition.  <b>Note: This equates to therapeutic trials in the previous versions of the guidelines.</b>                      Include a patient more than once if he/she participated in more than one interventional treatment trial during the reporting period.</p>

**Data Table 3 - Example Format**

**2P30CA120212-09**

Outstanding University Cancer Center  
 Reporting Period **MM/DD/YYYY – MM/DD/YYYY**  
 Data Table 3 – Newly Registered Patients /Participation in Interventional Treatment Trials  
 by Anatomic Cancer Site

<b>ReportingSource: Outstanding University Cancer Center</b>			<b>PrimarySite*</b>	<b>Registered Patient</b>	<b>Enrolled Patient</b>
<b>GrantNumber</b>	<b>Reporting Start Date</b>	<b>Reporting End Date</b>			
120212	01/01/2013	12/31/2013	Lip, Oral Cavity and Pharynx	85	0
120212	01/01/2013	12/31/2013	Esophagus	62	3
120212	01/01/2013	12/31/2013	Stomach	181	4
120212	01/01/2013	12/31/2013	Small Intestine	0	0
120212	01/01/2013	12/31/2013	Colon	728	17
120212	01/01/2013	12/31/2013	Rectum	50	10
120212	01/01/2013	12/31/2013	Anus	9	0
120212	01/01/2013	12/31/2013	Liver	121	6
120212	01/01/2013	12/31/2013	Pancreas	52	8
120212	01/01/2013	12/31/2013	Other Digestive Organ	174	8
120212	01/01/2013	12/31/2013	Larynx	50	2
120212	01/01/2013	12/31/2013	Lung	1257	50
120212	01/01/2013	12/31/2013	Other Respiratory and Inthoracic Organs	105	18
120212	01/01/2013	12/31/2013	Bones and Joints	25	6
120212	01/01/2013	12/31/2013	Soft Tissue	35	3
120212	01/01/2013	12/31/2013	Melanoma, skin	81	15
120212	01/01/2013	12/31/2013	Kaposi's sarcoma	21	0
120212	01/01/2013	12/31/2013	Mycosis Fungoides	23	0
120212	01/01/2013	12/31/2013	Other Skin	6	1
120212	01/01/2013	12/31/2013	Breast – Female	1203	54
120212	01/01/2013	12/31/2013	Breast – Male	1	0
120212	01/01/2013	12/31/2013	Cervix	60	5
120212	01/01/2013	12/31/2013	Corpus Uteri	602	35
120212	01/01/2013	12/31/2013	Ovary	49	1
120212	01/01/2013	12/31/2013	Other Female Genital	33	0
120212	01/01/2013	12/31/2013	Prostate	382	17
120212	01/01/2013	12/31/2013	Other Male Genital	22	0
120212	01/01/2013	12/31/2013	Urinary Bladder	188	12
120212	01/01/2013	12/31/2013	Kidney	183	1
120212	01/01/2013	12/31/2013	Other Urinary	10	1
120212	01/01/2013	12/31/2013	Eye and Orbit	6	0
120212	01/01/2013	12/31/2013	Brain & Nervous System	932	269
120212	01/01/2013	12/31/2013	Thyroid	188	0

CCSG Electronic Data Guide (eData)

<b>ReportingSource: Outstanding University Cancer Center</b>			<b>PrimarySite*</b>	<b>Registered Patient</b>	<b>Enrolled Patient</b>
<b>GrantNumber</b>	<b>Reporting Start Date</b>	<b>Reporting End Date</b>			
120212	01/01/2013	12/31/2013	Other Endocrine System	21	0
120212	01/01/2013	12/31/2013	Non-Hodgkin's Lymphoma	190	41
120212	01/01/2013	12/31/2013	Hodgkin's Lymphoma	10	0
120212	01/01/2013	12/31/2013	Multiple Myeloma	307	141
120212	01/01/2013	12/31/2013	Lymphoid Leukemia	37	26
120212	01/01/2013	12/31/2013	Myeloid and Monocytic Leukemia	154	111
120212	01/01/2013	12/31/2013	Leukemia, other	1	0
120212	01/01/2013	12/31/2013	Other Hematopoietic	83	37
120212	01/01/2013	12/31/2013	Unknown Sites	118	0
120212	01/01/2013	12/31/2013	Ill-Defined Sites	3	13
<b>TOTAL:</b>				<b>7945</b>	<b>924</b>

\* Please use the 43 predefined Primary Site categories as listed. Altering the list will make processing the data less efficient.

## SECTION 4. DATA TABLE 4 - INFORMATION ON CLINICAL RESEARCH STUDIES

Create one record for each clinical research study and use the following column names and definitions for clarity and uniformity. *For a study with multiple PI, please create an individual record for each PI.*

**Table 4-1: Data Table 4 Column Definitions**

Column Name	SQL-Server Data Type /Format	Definition
GrantNumber	Int	The unique identification number for the P30 grant ( <i>e.g.</i> , 6929, 103693)
ReportingStartDate	DateTime MM/DD/YYYY	The date on which the center-defined 12-month reporting period started
ReportingEndDate	DateTime MM/DD/YYYY	The date on which the center-defined 12-month reporting period ended
ClinicalResearchCat	Varchar(15)	The Clinical Research Category in which the clinical research or protocol is listed Valid entry: INT, OBS, or ANC/COR <i>Note, this column is previously known as Section</i>
StudySource	Char(1)	The category of the trial sponsor or Study Source Valid entry: N, E, I, or D N - National Cooperative group E - Externally Peer-Reviewed I – Institutional D – Industry <i>Note, this column is previously known as Sponsor “Category”</i>
SpecificFundingSource	Varchar(100)	The specific name of the financial sponsor for the clinical research study. For institutionally sponsored trials or studies, list the name of the applicable funding agencies, ( <i>e.g.</i> , NCI, NYU) <i>Note, this column is previously known as Sponsor 1,2,3,or 4.</i>
IsMultiInst	Char(1)	Indicate whether the study is a multiple institutions; use “Y” for yes and “N” for no.
Site	Varchar(255)	The primary anatomic cancer site(s) ( <i>i.e.</i> , breast, ovary) the clinical research study focuses on. If the clinical research study is broadly applicable to a number of potential anatomic sites, enter the term “multiple” in this column.

CCSG Electronic Data Guide (eData)

Column Name	SQL-Server Data Type /Format	Definition
ProtocolID	Varchar(50)	The unique identifier for this study. For both national and externally reviewed trials, list the common protocol number that the trial is known under nationally, if one exists. For other types of trials, use an internal protocol identification or IRB number.
IsMultiPI	Char(1)	Indicate whether this is a multiple PI study ; use “Y” for yes and “N” for no.
PILastName	Varchar(25)	The last name of the Principal Investigator from your Center who is responsible for this Clinical Research Study
PIFirstName	Varchar(25)	The first name or initial of the Principal Investigator from your Center who is responsible for this Clinical Research Study <i>Do not include a period (.)</i>
PIMiddleName	Varchar(25)	The middle name or initial of the Principal Investigator from your Center who is responsible for this Clinical Research Study <i>Do not include a period (.)</i>
ProgCode	Varchar(5)	An alphanumeric Program Code that identifies the Research Program affiliated with the clinical research study as defined by the Center in Data Tables 1B and 2A. For clinical research studies that span more than one Research Program, include both Program Codes in this column. Refer to the Falls, R. example in the CCSG Data Guide
OpenDate	DateTime MM/DD/YYYY	The official start date (activation) of a trial determined as follows 1) the date of activation noted in an official clinical trial activation announcement or 2) date of first patient accrual if the trial in question did not have a formal activation announcement.
CloseDate	DateTime MM/DD/YYYY	The date the clinical research study closed to accrual. If the study is still open, leave this field blank
Phase	Varchar(255)	For Interventional studies acceptable phases include: pilot, feasibility, 0, I, II, III, IV, or combinations ( <i>e.g.</i> , “Pilot/Feasibility”, “I/II”). For epidemiologic, cancer control/behavioral, observational, ancillary, correlative or other biological studies, indicate “N/A” <i>Note, do not include blank spaces</i>
PrimaryPurpose	Varchar(3)	The type or primary purpose of clinical trial Valid entry: Tre, Pre, Sup, Scr, Dia, Hsr, Bas, or Oth <i>Note, this column is previously known as Study Type</i>
OfficialTitle	Varchar(8000)	Official name of the protocol provided by the study principal investigator or sponsor (Limit: 600 characters or fewer).

CCSG Electronic Data Guide (eData)

Column Name	SQL-Server Data Type /Format	Definition
EntireStudy	Int	The total targeted accrual for the entire study. For both single-site and multi-site trials initiated at your Center, indicate the total number of participants needed for the entire study. For multi-site trials that your Center participates in but did not initiate, leave this column empty. <i>Do not submit a targeted range, such as “10 – 100.”</i> Refer to Examples 1 – 3 in the CCSG Data Guide.
YourCenterTotal	Int	The targeted accrual for your Center. For single-site and multi-site trials initiated at your Center, indicate the total number of participants your Center is expected to accrue for the study. <i>Do not submit a targeted range, such as “10 – 100.”</i> Refer to Examples 1 – 3 in the CCSG Data Guide.
Center12Mos	Int	Provide the number of participants accrued to this clinical research study during the identified 12-month reporting period study your Cancer Center and its formal Consortium Partners.
CenterToDate	Int	Provide the number of participants accrued to this clinical research study to date at your Cancer Center and its formal Consortium Partners. This number is a cumulative figure, not an annual total.
Other12Mos	Int	Provide the number of participants accrued to this clinical research study during the identified 12-month reporting period at all hospitals, treatment facilities, and/ or research facilities that are not a formal part of the Cancer Center ( <i>e.g.</i> , nearby community hospitals or other Centers that are participating in multi-site trials led by your Cancer Center).
OtherToDate	Int	Provide the number of participants accrued in the clinical research study to date at all hospitals, treatment facilities, and/ or research facilities that are not a formal part of the Cancer Center ( <i>e.g.</i> , nearby community hospitals or other Centers that are participating in multi-site trials led by your Cancer Center). This number is a cumulative figure, not an annual total.

Ctrl-Click on the following link for the [Data Table 4 Format Sample](#).

## **APPENDIX A. DATA TABLE EXAMPLE FORMAT**

[Data Table 1A Example Format](#)

2P30CA120212-09

Outstanding University Cancer Center  
 Reporting Date: MM/DD/YYYY  
 Data Table 1A- Senior Leadership

GrantNumber	Reporting Date	LastName	FirstName	MiddleName	isNew	Title	Degree1	Degree2	Degree3
120212	01/01/2013	Sutton	Baylor	T	N	Director and Principal Investigator	MD	PhD	
120212	01/01/2013	Marucco	Gina	Elizabeth	N	Deputy Director	PhD		
120212	01/01/2013	Galley	Mark		N	Assoc. Director for Basic Science	MD		
120212	01/01/2013	Barrie	Thomas	Ellen	Y	Assoc. Director for Clinical Research	MD	PhD	MS
120212	01/01/2013	Wong	Lee	Q.	N	Assoc. Director for Population Research	PhD		

[Data Table 1B Example Format](#)

2P30CA120212-09

Outstanding University Cancer Center  
 Reporting Date: MM/DD/YYYY  
 Data Table 1B – Programs Leaders

Grant Number	Reporting Date	Prog Code	ProgName	IsNewProg	IsDevProg	IsMulti Leader	LastName	FirstName	Middle Name	Degree1	Degree2	Degree3	IsNew	Number Of Member
120212	01/01/2013	01	Molecular and Cellular Biology	N	N	N	Harrington	Marc	F.	MD	PhD		N	25
120212	01/01/2013	02	Cancer Control and Prevention	Y	N	Y	Pham	Phuong	Duong	PhD			N	14
120212	01/01/2013	02	Cancer Control and Prevention	Y	N	Y	Wilson	Gail		PhD			N	
120212	01/01/2013	03	Epidemiology	N	N	N	Kaufman	Richard	W.	MD	PhD		N	19
120212	01/01/2013	03	Epidemiology	N	N	N	Smith	Hanson		PhD			N	19
120212	01/01/2013	04	Developmental Therapeutics	N	N	Y	Wood	Mary		MD	PhD		N	15
120212	01/01/2013	04	Developmental Therapeutics	N	N	Y	Storm	John		MD	PhD		N	
120212	01/01/2013	05	Women's Cancers	N	N	N	Miller	Barbara	Jasmine	PhD			N	22
120212	01/01/2013	CCG	Cell Cycle and Growth Control	N	N	N	Neuhauser	Beverly					N	12
120212	01/01/2013	IM	Immunology	N	N	N	Bhorjee	Jaswant	S.	MD	PhD		Y	27
120212	01/01/2013	ZY	Non-Aligned Members											12

[Data Table 1C Example Format](#)

2P30CA120212-09

Outstanding University Cancer Center  
Reporting Date: MM/DD/YYYY  
Data Table 1C – Cancer Center Membership

GrantNumber	Reporting Date	AlignedNumber	NonAlignedNumber	GrantTotal
120212	01/01/2013	134	12	146

Data Table 1D Example Format

2P30CA120212-09

Outstanding University Cancer Center  
 Reporting Date: MM/DD/YYYY  
 Data Table 1D - Shared Resources

Grant Number	Reporting Date	SRName	Sub Cat1	Sub Cat2	Sub Cat3	IsNewSR	IsDevSR	IsMulti Director	LastName	FirstName	MiddleName	Degree 1	Degree 2	Degree 3	Is New
120212	01/01/2013	Biostatistics	6.01			N	N	N	Francini	Benjamin		PhD			Y
120212	01/01/2013	DNA Microarray	1.35	4.05		N	Y	N	Poole	Bruce	J	PhD			N
120212	01/01/2013	DNA Sequencing	1.22	1.35		N	N	N	Kelley	Steven		MD	PhD		N
120212	01/01/2013	Genomics and Proteomics	1.36			Y	N	N	Goldstein	Phillip		PhD			N
120212	01/01/2013	Bioinformatics	7.02			N	N	N	Mayrend	Jody	Kim	MD	PhD		N
120212	01/01/2013	Organic Synthesis	1.12			N	N	N	Singer	Richard		MD	PhD		Y
120212	01/01/2013	Transgenic Animal Facility *	1.03	1.06	1.09	N	N	Y	Peterson	Douglas	John	MD			N
120212	01/01/2013	Transgenic Animal Facility *	1.03	1.06	1.09	N	N	Y	Barns	Nancy	E.	PhD			N

\* Note that the Transgenic Animal Facility has two Shared Resource Directors Dr. Peterson and Dr. Barns.  
 For a share resource with multiple directors, please provide a row of record for each director.

CCSG Electronic Data Guide (eData)

Data Table 2A - Example Format

2P30CA120212-09

Outstanding University Cancer Center  
Reporting Date: MM/DD/YYYY  
Data Table 2A – Active Funded Projects

Grant Number	Reporting Date	PI LastName	PI First Name	PI Middle Name	Is Multi PI	ProjNumber	Is Peer Rev	IsSub Contract	Specific Funding Source	Proj Start Date	Proj End Date	ProjTitle	Annual Proj Direct Cost	Annual Proj Total Cost	Prog Code	Prog Percent	Annual Prog Direct Cost	Annual Prog Total Cost
120212	01/01/2013	Farber	J		N	2P01HL070149-10	Y	Y	NHLBI Case Western	6/1/2013	5/31/2018	MECHANISMS OF GVHDProj 1: Human Minor histocompatibility Antigens	80000	104000		40	32000	41600
120212	01/01/2013	Jones	J		N	2P01HL070149-10	Y	Y	NHLBI Case Western	6/1/2013	5/31/2018	MEC NISMS OF GVHD Core B: Biostatistics Core	40000	52000	ZY	20	8000	10400
120212	01/01/2013	Alfred	L		N	1R01CA059736-01	Y	N	NCI	6/1/2010	5/30/2015	Regulation of mitochondrial inheritance in yeast	200000	260I000		100	200000	260000
120212	01/01/2013	Alison	S		N	LLS 7080-06 7004-11	Y	N	Leukemia & Lymphoma Society	10/1/2005	9/30/2015	Experimental Therapeutics in CLL	1000000	1300000		100	1000000	1300000
120212	01/01/2013	Birmann	B		Y	3R01NS046045-03	Y	N	NINDS	3/1/2012	2/28/2017	Targeting the anti-apoptotic protein survivin in glioma	140000	182000		20	28000	36400
120212	01/01/2013	Glick	D			3R01NS046045-03			UAB	3/1/2012	2/28/2017							
120212	01/01/2013	Christy	W		N	RPG-96-045-04-1	Y	N	ACS	1/1/2005	12/31/2010	The role of an HNF-3 protein in c elegans foregut development	104000	135200		100	104000	135200
120212	01/01/2013	Donegan	A		N	3R01HL086850-3S2	Y	Y	NHLBI Dartmouth	8/1/2012	7/30/2013	Calpain and p120 catenin regulation of cadherin function	50000	65000		20	10000	13000
120212	01/01/2013	Dubois	Y		N	5R01CA067893-02	Y	N	NCI	9/1/2012	8/30/2017	Star trial (Tamoxifen vs. Raloxifene)	100000	130000		60	60000	78000

CCSG Electronic Data Guide (eData)

Grant Number	Reporting Date	PI LastName	PI First Name	PI Middle Name	Is Multi PI	ProjNumber	Is Peer Rev	IsSub Contract	Specific Funding Source	Proj Start Date	Proj End Date	ProjTitle	Annual Proj Direct Cost	Annual Proj Total Cost	Prog Code	Prog Percent	Annual Proj Direct Cost	Annual Proj Total Cost	
120212	01/01/2013	Dubois	Y		N	5R01CA067893-02	Y	N	NCI	9/1/2012	8/30/2017	Star trial (Tamoxifen vs. Raloxifene)			5	40	40000	52000	
120212	01/01/2013	Gordon	E		N	TAS 75 0849	Y	N	NCI	1/1/2012	12/31/2018	Surveillance, Epidemiology, and End Results Program	400000	520000	ZY	100	400000	520000	
120212	01/01/2013	Isaac	M		Y	1R01AI051273-01	Y	N	NIAID	10/1/2013	9/30/2016	Novel Approaches to Detect Virus-Cancer Associations	480000	624000	2	100	480000	624000	
120212	01/01/2013	News	H			1R01AI051273-01			NIAID	10/1/2013	9/30/2016								
120212	01/01/2013	John	E		Y	1205439	Y	N	NSF	5/1/2012	4/30/2015	mHealth - Computing Infrastructure for Mobile Health and Wellness Monitoring	600000	780000	ZY	10	60000	78000	
120212	01/01/2013	Sir	P			1205439			NSF	5/1/2012	4/30/2015								
120212	01/01/2013	Lee	R		N	5P50CA119997-04	Y	N	NCI	3/1/2012	2/28/2017	SPORE in Lung Cancer	1000000	1300000					
120212	01/01/2013	Lee	R		N	5P50CA119997-04	Y	N	NCI	3/1/2012	2/28/2017	Proj 2: Anti-tumor Mechanisms of SRC Inhibitors in Lung Cancer			2	100	250000	000	
120212	01/01/2013	Lee	R		N	5P50CA119997-04	Y	N	NCI	3/1/2012	2/28/2017	SPORE in Lung Cancer Proj 1: E2F's Impact on Therapeutic Efficacy			ZY	100	40000	52000	
120212	01/01/2013	Grant	U			5P50CA119997-04			NCI	3/1/2012	2/28/2017								

CCSG Electronic Data Guide (eData)

Grant Number	Reporting Date	PI LastName	PI First Name	PI Middle Name	Is Multi PI	ProjNumber	Is Peer Rev	IsSub Contract	Specific Funding Source	Proj Start Date	Proj End Date	ProjTitle	Annual Proj Direct Cost	Annual Proj Total Cost	Prog Code	Prog Percent	Annual Proj Direct Cost	Annual Proj Total Cost
120212	01/01/2013	Lee	R		N	5P50CA119997-04	Y	N	NCI	3/1/2012	2/28/2017	SPORE in Lung Cancer: Core A: Tissue Procurement, Pathology, and Bioinformatics			ZY	100	185000	240500
120212	01/01/2013	Jackson	A			5P50CA119997-04			NCI	3/1/2012	2/28/2017							
120212	01/01/2013	Lee	R		N	5P40CA119997-04	Y	N	NCI	3/1/2012	2/28/2017	SPORE in Lung Cancer Proj 1: E2F's Impact on Therapeutic Efficacy			I	100	220000	286000
120212	01/01/2013	Sherman	W			5P40CA119997-04			NCI	3/1/2012	2/28/2017							
120212	01/01/2013	Smith	W			5P40CA119997-04			NCI	3/1/2012	2/28/2017							
120212	01/01/2013	Lee	R		N	5P50CA119997-04	Y	N	NCI	3/1/2012	2/28/2017	SPORE in Lung Cancer: RRM1 in the Management of Lung Cancer			I	100	225000	292500
120212	01/01/2013	Stuart	J			5P50CA119997-04			NCI	3/1/2012	2/28/2017							
120212	01/01/2013	Mellon	C		N	5R01DK053265-03	Y	N	NIDDK	2/1/2013	1/31/2018	In vivo Selection for Stem Cell Gene Therapy	600000	780000	ZY	20	120000	182000
120212	01/01/2013	Murphy	J		N	3P30CA022354-0S3	Y	N	NCI	5/1/2013	4/30/2014	Cancer Center Support Grant: Community Health Educator	140000	182000	ZY	100	140000	182000
120212	01/01/2013	Newton	C		Y	1R01AI051273-01	Y	N	NIAID	10/1/2013	9/30/2016	Novel Approaches to Detect Virus-Cancer Associations	\$320,000	\$416,000	3	100%	\$320,000	\$416,000

CCSG Electronic Data Guide (eData)

Grant Number	Reporting Date	PI LastName	PI First Name	PI Middle Name	Is Multi PI	ProjNumber	Is Peer Rev	IsSub Contract	Specific Funding Source	Proj Start Date	Proj End Date	ProjTitle	Annual Proj Direct Cost	Annual Proj Total Cost	Prog Code	Prog Percent	Annual Proj Direct Cost	Annual Proj Total Cost
120212	01/01/2013	Isaac	M			1R01AI051273-01			NIAID	10/1/2013	9/30/2016							
120212	01/01/2013	Newton	C		Y	2R01CA055747-06	Y	N	NCI	9/1/2012	8/30/2015	Epidemiologic and Genetic Studies of Breast Cancer	480000	624000	4	100	480000	624000
120212	01/01/2013	Fish	F			2R01CA055747-06			UNC	7/18/2011	6/30/2014							
120212	01/01/2013	Persky	D		N	S1001	Y	N	NCI	7/18/2011	6/30/2014	A Phase II Trial of R-CHOP followed by Yttrium-90 Ibritumomab tiuxetan for Early Stage Diffuse Large B-cell Lymphoma	215000	279500	5	100	215000	279500
120212	01/01/2013	Sir	P		Y	1205439	Y	N	NSF	5/1/2012	4/30/2015	mHealth - Computing Infrastructure for Mobile Health and Wellness Monitoring	628000	816400	1	10	62800	81640
120212	01/01/2013	John	E			1205439			NSF	5/1/2012	4/30/2015							
120212	01/01/2013	Smith	K		N	5P30CA010518-42	Y	N	NCI	4/1/2011	3/31/2016	Consolidated Basic Cancer Research Program	2500000	3250000	ZY	100	2500000	3250000
120212	01/01/2013	Smith	K		N	5P30CA010518-42S1	Y	N	NCI	4/1/2011	3/31/2016	Consolidated Basic Cancer Research Program: CURE Supplement	120000	156000	ZY	100	120000	156000
120212	01/01/2013	Hay	J		N	DAMD1702-1-11	Y	N	DOD	9/1/2013	8/31/2015	Molecular study of bag domains: A new motif in prostate cancer	\$45,000	\$58,500	T	100%	\$45,000	58,500
120212	01/01/2013	Kahl	C		N	5F32HL069595-02	Y	N	NHLBI	7/1/2010	6/30/2013	Differentiation of a stem cell population in vivo	\$36,000	\$46,800	T	50%	\$18,000	23,400
120212	01/01/2013	Larson	A		N	5K08HL001711-04	Y	N	NHLBI	2/1/2012	1/30/2015	Serotonergic mechanisms is stress and anxiety	\$170,000	\$221,000	T	20%	\$34,000	44,200

CCSG Electronic Data Guide (eData)

Grant Number	Reporting Date	PI LastName	PI First Name	PI Middle Name	Is Multi PI	ProjNumber	Is Peer Rev	IsSub Contract	Specific Funding Source	Proj Start Date	Proj End Date	ProjTitle	Annual Proj Direct Cost	Annual Proj Total Cost	Prog Code	Prog Percent	Annual Proj Direct Cost	Annual Proj Total Cost
120212	01/01/2013	Jones	B		N	1T32CA009579-01	Y	N	NCI	5/1/2008	4/30/2013	Cell adhesion and effects on cell behavior	\$25,000	\$32,500	T	100%	\$25,000	32,500
120212	01/01/2013	Miller	L		N	3568	N	N	Breast Cancer Res. Fdn.	10/1/2010	9/30/2015	Breast cancer prevention through nutrition program	\$1,100,000	\$1,430,000	2	100%	\$1,100,000	\$1,430,000
120212	01/01/2013	Norris	C		N	4786	N	N	Am.-Italian Cancer Foundation	7/1/2012	6/30/2017	MicroRNAs as predictors of (pre)malignant phenotype in cystic neoplasms of the pancreas	\$90,000	\$117,000	1	90%	\$81,000	\$105,300
120212	01/01/2013	Pope	B		N	N/A	N	N	Vical	7/1/2014	12/21/2016	Phase II Trial of Allovectin-7 for Metastatic Melanoma	\$250,000	\$325,000	4	100%	\$250,000	\$325,000

Data Table 2B Example Format

2P30CA120212-09

Outstanding University Cancer Center  
 Reporting Date: MM/DD/YYYY  
 Data Table 2B – Active Funded Projects

Grant Number	Reporting Date	NCI TotalNo	NCI DirectCost	NCI TotalCost	OthNIH TotalNo	OthNIH DirectCost	OthNIH TotalCost	OthPeer TotalNo	OthPeer DirectCost	OthPeer TotalCost	Industry NonPeer TotalNo	Industry NonPeer DirectCost	Industry NonPeer TotalCost	Oth NonPeer TotalNo	Oth NonPeer DirectCost	Oth NonPeer TotalCost
120212	01/01/2013	14	5180000	6734000	9	1916000	2490800	5	2377000	3090100	2	325000	422500	4	1706900	1313000

CCSG Electronic Data Guide (eData)

**Data Table 4 - Example Format**

**2P30CA120212-09**

Outstanding University Cancer Center  
 Reporting Period: MM/DD/YYYY – MM/DD/YYYY  
 Report Prepared: MM/DD/YYYY  
 Data Table 4 - Clinical Research Protocols

Grant Number	Reporting Start Date	Reporting End Date	Clinical Research Cat	Study Source	Specific Funding Source	Site	Protocol ID	Is Multi Inst	PI LastName	PI First Name	PI Middle Name	Prog Code	OpenDate	Close Date	Phase	Primary Purpose	Title	Entire Study	Your Center Total	Center 12mos	Center ToDate	Other 12 mos	Other To Date
120212	01/01/2013	12/31/2013	INT	N	RTOG	Bladder	RTOG 0712	Y	Armstrong	C	John	2	8/15/2013		III	Tre	Randomized chemo/rt/surg for bladder cancer		220	82	120		
120212	01/01/2013	12/31/2013	INT	N	CALGB	Myeloid leukemia	10603	Y	Kane	Steve		8	4/21/2012		III	Tre	Induction & Consolidation Chemo + Midostaurin v Placebo in Newly Diagnosed FLT3 Mutated AML		70	28	49		
120212	01/01/2013	12/31/2013	INT	N	COG	Myeloid leukemia	COG-08H9	Y	Lehr	D		4	5/1/2012		I	Tre	Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia		6	0	4		
120212	01/01/2013	12/31/2013	INT	E	NYU, NCI	Multiple	NCI-1109	Y	Mack	Frank	D	3	8/1/2012		III	Sup	Preparatory Aid to Improve Decision Making about Cancer Clinical Trials (PRE- ACT)	400	60	22	46	70	240
120212	01/01/2013	12/31/2013	INT	E	NCI	Colon, Rectum	NCI 06-8-01	N	Shephard	A		2	12/5/2014		II	Pre	Polyethylene Glycol For ACF Reduction and Biomarker Modulation in Individuals with CRC Risk	140	140	34	68		

CCSG Electronic Data Guide (eData)

Grant Number	Reporting Start Date	Reporting End Date	Clinical Research Cat	Study Source	Specific Funding Source	Site	Protocol ID	Is Multi Inst	PI LastName	PI First Name	PI Middle Name	Prog Code	OpenDate	Close Date	Phase	Primary Purpose	Title	Entire Study	Your Center Total	Center 12mos	Center ToDate	Other 12 mos	Other To Date
120212	01/01/2013	12/31/2013	INT	I	NYU	Breast	NYU-1054	N	Allen	Thomas		2	2/14/2013		I/II	Sup	Dose Finding and Tolerability ALA in Paclitaxel Induced Neuropathy Pts.	30	30	4	10		
120212	01/01/2013	12/31/2013	INT	I	NYU	Lymphoma	NYU-5150	N	Bates	S		4	5/1/2012		I	Tre	Ofatumumab for inindolent B-cell lymphomas		6	0	4		
120212	01/01/2013	12/31/2013	INT	I	NYU	Multiple	NYU-1133	Y	Dunn	R	Cherel	1	7/4/2015		II	Pre	Restasis Vs Placebo in Primary Prevention of Ocular GVHD	14	6	2	5	2	8
120212	01/01/2013	12/31/2013	INT	I	NYU	Multiple	NU-0521	N	Hook	S		10	1/17/2013		II	Sup	Etanercept in Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor SCT	105	105	10	30		
120212	01/01/2013	12/31/2013	INT	D	GSK	Leukemia	GSK 0806	N	Day	Patricia		10	3/1/2013		I	Sup	Phase 1 Trial of Palifermin for Oral Mucositis	15	15	6	8		
120212	01/01/2013	12/31/2013	INT	D	BMS	Lymphoid leukemia	DRUG - 5013	N	Head	R		8	5/1/2014		III	Tre	Lenalidomide as Maintenance Therapy for Patients with B-cell CLL		113	47	79		
120212	01/01/2013	12/31/2013	OBS	E	NCI	Brain and Nervous System	NCI-2902	N	Falls	R	D	8 & 10	7/2/2012		N/A	Oth	Neurocognitive outcomes in pediatric brain tumor survivors following proton beam XRT vs conventional XRT	100	100	13	30		

CCSG Electronic Data Guide (eData)

Grant Number	Reporting Start Date	Reporting End Date	Clinical Research Cat	Study Source	Specific Funding Source	Site	Protocol ID	Is Multi Inst	PI LastName	PI First Name	PI Middle Name	Prog Code	OpenDate	Close Date	Phase	Primary Purpose	Title	Entire Study	Your Center Total	Center 12mos	Center ToDate	Other 12 mos	Other To Date
120212	01/01/2013	12/31/2013	OBS	E	American Cancer Society	Prostate	ACS-2162	Y	Rogers	Seldon		6	9/5/2014		N/A	Oth	Focus group evaluation of prostate cancer symptom management education materials	30	14	6	8	7	14
120212	01/01/2013	12/31/2013	OBS	E	NCI	Ovarian	NCI-3315	N	Lemon	J	Joseph	3	6/1/2013		N/A	Oth	Exogenous hormone use and risk of ovarian cancer		50	12	49		
120212	01/01/2013	12/31/2013	OBS	I	NYU	Multiple	NYU-1926	Y	Berry	June		08	5/1/2015		N/A	Oth	Risk factors for childhood cancer and hematological disorders by case-control studies	4000	1500	125	499	86	600
120212	01/01/2013	12/31/2013	OBS	I	NYU, NIH	Multiple Myeloma	NYU-1007	N	Smith	S		08	1/1/2010	4/7/2011	N/A	Oth	Treatment Decision Making in Older Adults Newly Diagnosed with MM		20	6	18		
120212	01/01/2013	12/31/2013	ANC/COR	I	NYU	Brain	NYU-1762	N	Okra	Selby		08	2/23/2016		N/A	Bas	Phase I & 2 drug metabolism polymorphisms & outcome in children with medulloblastoma	54	54	10	36		
120212	01/01/2013	12/31/2013	ANC/COR	I	NYU	Leukemia	NYU-2701	Y	Granger	I		08	6/15/2010		N/A	Bas	Prospective observational trial of telomere length and telomerase mutations in pediatric AML	50	30	12	25	8	18
120212	01/01/2013	12/31/2013	ANC/COR	I	NYU	Leukemia	NYU-0631	N	Down	R	R	08	2/30/2014		III	Oth	Comparison of Acute and Long-term Toxicities in BM Donors w/wout G-CSF Treatment Prior to Harvest		206	48	89		

CCSG Electronic Data Guide (eData)

Grant Number	Reporting Start Date	Reporting End Date	Clinical Research Cat	Study Source	Specific Funding Source	Site	Protocol ID	Is Multi Inst	PI LastName	PI First Name	PI Middle Name	Prog Code	OpenDate	Close Date	Phase	Primary Purpose	Title	Entire Study	Your Center Total	Center 12mos	Center ToDate	Other 12 mos	Other To Date
120212	01/01/2013	12/31/2013	ANC/COR I		NYU	Other hemapoietic	NYU-0898	N	Gosden,	Robert		08	2/4/2015		N/A	Bas	Biology Study of Transient Myeloproliferative Disorder (TMD) in Children with Down Syndrome (DS)		17	1	3		